Evidence map›Paper›PMID 36451226›Full record

ArticleAddiction science & clinical practice2022

Tobacco cessation among smokers under substance use treatment for alcohol and/or cannabis: study protocol and pilot study.

Ariadna Feliu, Esteve Fernández, Yolanda Castellano, Marta Enríquez, Judith Saura, Carmen Cabezas, Joan Colom, Josep M Suelves, Margarida Pla, Mar Parejo and 11 more

Registry-linked trialAbstract read
In one paragraph

Article in Addiction science & clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04841655 (Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04841655 unknown statusnot on this map

Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment

TypeobservationalSponsorInstitut Català d'OncologiaRan2020 to 2022Enrolled1,625ConditionsMental Health Disorder, Substance Abuse Drug, Alcohol Abuse, Cannabis Use
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ariadna FeliuTobacco Control Unit, Cancer Control and Prevention Program, WHO Collaborating Center On Tobacco Control, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Esteve FernándezTobacco Control Unit, Cancer Control and Prevention Program, WHO Collaborating Center On Tobacco Control, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Yolanda CastellanoTobacco Control Unit, Cancer Control and Prevention Program, WHO Collaborating Center On Tobacco Control, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Marta EnríquezTobacco Control Unit, Cancer Control and Prevention Program, WHO Collaborating Center On Tobacco Control, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Judith SauraTobacco Control Unit, Cancer Control and Prevention Program, WHO Collaborating Center On Tobacco Control, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Carmen CabezasGovernment of Catalonia, Public Health Secretariat, Barcelona, Spain.
Joan ColomPublic Health Agency of Catalonia, Barcelona, Spain.
Josep M SuelvesPublic Health Agency of Catalonia, Barcelona, Spain.
Margarida PlaDepartment of Public Health, Maternal Health and Mental Health, School of Medicine and Health Sciences, Universitat de Barcelona, L'Hospitalet del Llobregat, Barcelona, Spain.
Mar ParejoDepartment of Public Health, Maternal Health and Mental Health, School of Medicine and Health Sciences, Universitat de Barcelona, L'Hospitalet del Llobregat, Barcelona, Spain.
Sílvia MondonAddictions Unit, Psychiatry Department, Institute of Neurosciences, Hospital Clínic de Barcelona, Barcelona, Spain.
Pablo BarrioAddictions Unit, Psychiatry Department, Institute of Neurosciences, Hospital Clínic de Barcelona, Barcelona, Spain.
Magalí AndreuAddictions Unit, Psychiatry Department, Institute of Neurosciences, Hospital Clínic de Barcelona, Barcelona, Spain.
Antonia RaichMental Health Department, Althaia Xarxa Assistencial Universitària, Manresa, Barcelona, Spain.
Jordi BernabeuMental Health Department, Althaia Xarxa Assistencial Universitària, Manresa, Barcelona, Spain.
Jordi VilaplanaSerra Húnter Fellow, Computer Science Department, Universitat de Lleida, Lleida, Spain.
Xavier RocaAddictive Behaviors Unit, Psychiatry Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
Pablo BautistaDepartment of Public Health, Maternal Health and Mental Health, School of Medicine and Health Sciences, Universitat de Barcelona, L'Hospitalet del Llobregat, Barcelona, Spain.
Joseph GuydishPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, 94158, USA.
Cristina MartínezTobacco Control Unit, Cancer Control and Prevention Program, WHO Collaborating Center On Tobacco Control, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain. cmartinez@iconcologia.net.ORCID 0000-0002-0108-3288
group of clinicians involved in the recruitment of the study

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApproximately 80% of people with a substance use disorder (SUD) are smokers. Starting SUD treatment offers the opportunity to also quit smoking. The ACT-ATAC project aims to identify the predictors associated with smoking cessation among persons treated for alcohol and/or cannabis use disorder in Barcelona. This manuscript reports its methodology and the experience of carrying it out during the COVID-19 pandemic.

methodsMixed methods project with three substudies. Substudy 1 (S1) comprises heterogeneous discussion groups among clinicians. S2 has two prospective cohorts composed of smokers under treatment for alcohol and/or cannabis use disorder and the clinicians in charge of these patients. Participating smokers will be followed for 12 months and interviewed about their substance use and the tobacco cessation services received using the Spanish version of the users' Knowledge, Attitudes, and Services (S-KAS) scale. The clinicians will be asked about their self-reported practices in smoking cessation using the Knowledge, Attitudes, and Practices (S-KAP) scale. S3 comprises heterogeneous discussion groups with smokers. Data will be triangulated using qualitative and quantitative analyses. To facilitate the recruitment process, the researchers have introduced several strategies (design clear protocols, set monthly online meetings, extend the project, provide gift cards, etc.). DISCUSSION: The results of S1 were used to develop the questionnaires. S2 required some adjustments due to the COVID-19 pandemic, particularly the follow-up interviews being conducted by phone instead of face-to-face, and the recruitment rhythm was lower than expected. Recruitment will last until reaching at least 200-250 users. The fieldwork could not have been possible without the collaboration of the ACT-ATAC team and the introduction of several strategies. Trial registration The ACT-ATAC project has been successfully registered at Clinicaltrials.gov [NCT04841655].

Indexed as

CannabisCOVID-19Marijuana AbuseSubstance-Related DisordersTobacco Use CessationEthanolHumansPandemicsPilot ProjectsProspective StudiesSmokersEthanolAlcoholCannabisSmoking cessationSubstance abuse

Identifiers

PMID36451226
PMCPMC9709380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.